Transformation Delayed: Execution Risk Is Far Worse Than Guidance Admits
ABD's transformation roadmap—backward integration, FTA benefits, brand relaunches—is solid on paper. But Q1's 1.8% revenue growth and 18.7% PAT decline reveal an execution risk that guidance has papered over. The market has repriced accordingly, down 12.9% from its all-time high.
₹45.4 Cr
-18.7% YoY
₹24 Cr
1.3% of revenue
~₹63 Cr
+13.6% YoY
On the surface, ABD's Q1 result looks punitive: revenue +1.8% YoY, reported PAT down 18.7%, EBITDA margin compressed to 12.2%. Management pins most of the decline on a ₹24 crore supply chain impact (global glass and packaging sourcing remains tight). Adjusted for this, PAT rises to roughly ₹63 crore, a +13.6% organic gain. But this adjusted number papers over the real story. The core tension isn't between acceptable and bad; it's between a weak delivery and an unsustainably aggressive guidance. To hit mid-to-high teens FY27 growth, Q2–Q4 must deliver 20%+ acceleration. That's a tall order when Q1 couldn't crack 2%.
Where the profit really sits
The supply chain story is credible: global sourcing remains tight, and geopolitical headwinds (Middle East, Ukraine) are real. Management expects this pressure to ease by Q2 maximum, with Q3–Q4 bounce-back. But this timeline is hostage to forces outside ABD's control. Even adjusted for supply chain drag, the profit story is weak: +13.6% YoY is respectable, but EBITDA was flat year-over-year (₹120 Cr vs ₹119 Cr prior year) despite gross margin gains of 277 bps. The reason is clear—premiumization investment and cost absorption are draining near-term profitability. This is not a sign of confidence about current-year momentum; it's a sign that management is betting on FY27–28 tailwinds to justify the capex outlay.
What management claimed vs. what the result shows
5.8% YoY growth in income from operations
OverstatedRevenue ₹1,809 Cr (+1.8% YoY); income from operations ₹984 Cr. Growth in operating income is inflated by a lower revenue base.
Mid-to-high teens FY27 revenue guidance
At acute riskQ1 delivered 1.8%. For mid-teens (15%+ CAGR), Q2–Q4 must average 20%+ quarterly growth—unproven at this company's scale.
Gross margin expanded 277 bps to 46%
SupportedReported 46%; like-to-like adjusted 48.4%. Expansion is real, but supply chain impact masks pricing power and product mix benefit.
ABD outperformed industry with 6.2% volume growth
Supported9M cases +6.2% vs industry low single-digit; P&A segment +10.7%, Mass Premium +2.3%. Volume beat is genuine.
PAT impacted by supply chain ₹24 Cr
SupportedSupply chain impact ₹24 Cr (1.3% of revenue) cited and reflected in adjusted PAT bridge to ₹63 Cr.
What changed on this call
ABD Maestro revenue expected to double: ₹40 Cr FY26 → ₹80 Cr FY27 guidance. Still unprofitable (3-year gestation disclosed), immaterial to consolidated results, but trajectory marks a strategic pivot to luxury. 10 brands, 5,500+ premium outlets, 6 countries.
Telangana government overdue quantified at ₹400 Cr. Management states mostly old overdue is cleared; recent supplies paid on time. Material working capital headwind if collection timeline extends further. No explicit collection risk flagged beyond 'government responsive to industry issues.'
Supply chain recovery timeline: MD expects maximum pressure 'up to Q2,' with Q3–Q4 recovery. Vague on recovery path; contingent on geopolitical de-escalation (Middle East, Ukraine). First proof point will be Q2 earnings and gross margin trend.
FY28 EBITDA margin target reaffirmed: 17–18%. Levers: backward integration 300 bps, India-UK FTA 130–140 bps, cost discipline. Requires Telangana price increase (timing TBD) + successful brand relaunches (unproven). Each lever carries execution risk.
Guidance maintained despite Q1 miss. MD privately tempted to upgrade to high-teens revenue + 18% EBITDA, but official guidance holds mid-to-high teens + 17–18%. Reflects either confidence in H2 recovery or conservative hedge against announcement risk.
The bull-bear ledger
The bull case:
ICONiQ White is a real franchise. +33.8% Q1, +87.8% FY26, 1M+ monthly production; world's fastest-growing millionaire whisky. State white-space remains (Karnataka, Telangana, AP); new channels (CSD defense listing); international expansion (10 countries). This is genuine momentum, not marketing spend.
Premiumization is structural tailwind. P&A now 59.3% of value mix (vs 55.8% prior year). This shift is industry-wide and favors ABD's portfolio positioning. Margin expansion embedded in the model if volumes follow.
Backward integration capex is on track and accretive. PET facility (Rangapur) commissioned FY26, already margin-accretive. Malt distillery expected H1 FY27; 300 bps margin benefit targeted by FY28. Structural capex, not a discretionary bet.
Cash generation strong. Operating cash flow ₹174 Cr in Q1; net debt reduced ₹33 Cr to ₹947 Cr. Leverage at 1.7x EBITDA and 0.6x equity—ample headroom for planned capex and debt service.
Export model is asset-light and high-margin. 39 countries (up from 36 Q4 FY26); superior working capital vs domestic; minimal capex intensity. ICONiQ and ABD Maestro expanding internationally.
The bear case:
Q1 1.8% growth vs mid-teens guidance = 20%+ H2 bet. Multiple simultaneous assumptions: supply chain recovery (geopolitical-dependent), successful brand relaunches (Officer's Choice Blue, B7 have 3+ years of high-teens CAGR decline; unproven turnarounds), new category launches (vodka, whisky H2 FY27 unproven), ICONiQ momentum at 15M cases scale (41% growth from 10.7M). Any one lever fails, guidance misses.
Non-ICONiQ P&A brands in structural decline. Officer's Choice Blue, Sterling B7, B10 down high-teens CAGR over 3 years. Management blamed prior cash flow constraints; plans packaging resets and communication refresh, but root competitive positioning issue is unaddressed. Relaunches are forward bets, not proven fixes.
Operating leverage absent. Revenue +5.8% (income from ops), but EBITDA flat YoY (₹120 vs ₹119 Cr). Despite 277 bps gross margin gain, premiumization investment and supply chain drag offset all leverage. Margin expansion promised in FY28, not delivered in FY27.
FY28 margin target 17–18% dependent on 5 uncertain levers: backward integration capex (300 bps, assumes timely execution + utilization), India-UK FTA (130–140 bps, regulatory/timing risk), Telangana price increase (timing TBD), new brand launch success, supply chain normalization. Any single lever fails = 100+ bps impact on target.
Telangana receivables risk. ₹400 Cr government overdue disclosed. Management states mostly old overdue cleared, recent supplies paid on time, but timing on residual collection unclear. Material working capital headwind if delayed. Government payment behavior remains opaque.
Supply chain recovery timeline speculative. MD expects 'maximum pressure up to Q2,' but global supply chain normalization is not in management's control. If Middle East or Ukraine tensions persist, Q3–Q4 recovery delayed and full-year margin target deteriorates further.
Portfolio concentration risk. ICONiQ driving nearly all P&A growth. At 3.1M cases Q1, scaling to 15M cases (41% growth needed) faces saturation risk and competitive intensity. Over-reliance on a single brand in a category where rival players are also aggressive.
How the street has repositioned
The market's initial verdict: day 1 +3.02%, day 3 +2.95%, day 5 +7.62%. On the surface, a clear thumbs-up for guidance. But the pop has faded since: the stock now trades ₹619.5, down 12.9% from its all-time high of ₹711.35, and sits below its 20-day simple moving average (₹636.76) while holding above the 50-day (₹615.4) and 200-day (₹561.15). RSI is 47.6—neutral, no conviction. The drawdown from ATH suggests investors are hedging: the previous rerating (from ₹561 to ₹711) priced in significant execution on the transformation thesis. ABD must now deliver it.
Institutional flows confirm the caution. FII ownership has trimmed 0.12 percentage points sequentially (Q3 FY26: 3.35% → Q4 FY26: 3.23%), while DII has inched up 0.21 pp (4.61% → 4.82%). Promoters remain stable at 80.91%. The modest FII selling—even as the stock rallied post-result—signals overseas institutions are not accumulating on the transformation narrative. Volume is normal (no panic). The combination—post-result pop that faded, stock down from ATH, FII trimming, RSI neutral—tells a story: the market gave management the benefit of the doubt initially, then re-risked the near-term execution challenges. This is a stock that must prove itself in H2 FY27.
Ranked risks for a holder
1
HIGHGuidance execution risk—need 20%+ H2 growth to hit mid-teens FY27 revenue
Q1 1.8% growth makes the full-year target contingent on simultaneous wins: supply chain recovery (geopolitical-dependent), brand relaunch success (unproven), new category launches, and ICONiQ scale momentum. If any lever fails or delays, guidance is cut and stock re-rates downward.
2
MEDIUM-HIGHFY28 margin target credibility—17–18% EBITDA requires 500+ bps expansion
Dependent on 5 concurrent levers: backward integration (300 bps, not yet visible), India-UK FTA (130–140 bps, regulatory/timing risk), Telangana price increase (uncertain), new brand success, supply chain normalization. If 2+ levers fail or delay, target is unachievable and credibility suffers.
3
MEDIUMTelangana government receivables—₹400 Cr overdue resolution
₹400 Cr is 22% of quarterly revenue, material to working capital and cash conversion. Management states mostly old overdue cleared and recent supplies paid on time, but timing on residual collection is vague. Delay extends receivable cycle and tightens cash flow.
4
MEDIUMSupply chain recovery timeline speculative—dependent on geopolitical normalization
MD expects pressure 'maximum up to Q2,' but global sourcing is not ABD's control point. If Middle East or Ukraine tensions persist, Q3–Q4 margin recovery is delayed, operating leverage remains absent in FY27, and full-year margin guidance comes under pressure.
5
MEDIUMBrand relaunch failure—Officer's Choice Blue, B7 structural decline unabated
Both brands down high-teens CAGR for 3+ years. Management plans packaging resets and communication refresh, but root competitive positioning issue is not addressed. If relaunches fail to arrest decline, P&A volume growth slows and near-term margin target slips.
6
MEDIUMPortfolio concentration—ICONiQ White is the only growth engine
ICONiQ now +33.8%, driving nearly all P&A growth. At 3.1M cases Q1, scaling to 15M cases (41% growth) will face saturation. Over-reliance on a single brand in a competitive category. If ICONiQ growth decelerates at scale, portfolio momentum stalls.
What to watch next
1 · Q2 supply chain normalization—does ₹24 Cr drag taper?
MD guided for 'maximum pressure up to Q2.' This is the first proof point. If supply chain impact persists beyond Q2, the recovery thesis breaks. Watch gross margin improvement and operating cash flow as watermarks—both should improve if sourcing normalizes.
2 · Brand relaunch traction—do Officer's Choice Blue and B7 stop the decline?
These brands have 3+ years of structural decline. Packaging resets and communication refreshes planned for H2 FY27. Early reads from UP market (OC Blue already in market) and B7 brand reset will validate or kill the turnaround bet. Portfolio momentum hinges on this.
3 · Telangana government price increase timing and ₹400 Cr overdue resolution
Critical to FY28 margin expansion and working capital. Management is 'very hopeful' on price hike after 'dialog ongoing,' but timing remains TBD. Also watch resolution of ₹400 Cr overdue—collection will improve cash conversion and de-risk the working capital cycle.
The debate
The number to track
Adjusted PAT (ex supply chain, one-time items). Reported PAT will bounce in Q2–Q3 if supply chain normalizes, but adjusted PAT is the real indicator of whether the core business is accelerating. If adjusted PAT growth hits 15%+ in FY27, the mid-teens revenue guidance is plausible. If it slows to single-digits, execution risk is real. Watch Q2 and Q3 adjusted PAT trends—they are the bridge between transformation story and actual delivery. This is the metric that should drive your hold/sell decision.
ABD is a steady business attempting a step-change transformation. But execution risk is high, and Q1 delivery suggests management ambition may outpace market reality. The stock's repricing (-12.9% from ATH) correctly reflects this caution. The transformation thesis is credible, but the proof is in H2 earnings. Hold for now; the market is right to hedge until then.
Transformation narrative vs. weak Q1: 1.8% growth, PAT down 18.7%
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Maintained mid-teens guidance despite Q1 miss; supply chain excuse is credible but recovery timeline is speculative. No prior-call numbers to compare track record.
Neutral
next 1–2 quarters
Optimistic
multi-year
ABD delivered 1.8% revenue growth and -18.7% PAT decline in Q1, sharply missing prior guidance. Management's mid-to-high teens FY27 growth target is at risk unless Q2-Q4 see sharp recovery post-supply-chain normalization. Long-term margin expansion (to 17-18% by FY28) is achievable via backward integration and FTA benefits, but near-term momentum is broken and P&A brand relaunch bets are unproven. Material Telangana receivables (₹400 Cr) add execution risk.
₹1809.2 Cr
Revenue · +1.8% YoY₹45.4 Cr
Reported PAT · −18.7% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
5.8% YoY growth in income from operations
OVERSTATEDOverall revenue grew only 1.8% YoY; income from operations ₹984 Cr vs. total revenue ₹1809.2 Cr
Mid-teens FY27 revenue guidance
MISSQ1 delivered only 1.8% growth; would need ~20%+ in Q2-Q4 to meet mid-teens
PAT at ₹45 Cr reflects supply chain impact of ₹24 Cr
METEven like-to-like adjusted PAT (₹63 Cr) is only +13.6% YoY; PAT margin compressed to 2.5%
Gross margin expanded 277 bps to 46%
METLike-to-like 48.4%; reported 46% reflects supply chain drag, but underlying strength acknowledged
ABD outperformed industry with 6.2% volume growth
METIndustry grew low single-digit; P&A grew 10.7%, Mass Premium 2.3%; volume claim checks out
Earnings quality
What changed since the last call
Guidance maintained despite Q1 miss
NeutralFY27 mid-teens guidance unchanged despite 1.8% Q1 growth; MD privately tempted to upgrade to high-teens but official guidance holds. Reflects confidence in H2 recovery or hedging against announcement risk
FY28 margin target reaffirmed
Maintained17-18% EBITDA margin by FY28 consistent with prior calls; 300 bps backward integration + 130-140 bps FTA benefits articulated. Q1 delivered 12.2% (adjusted 14.7%); implies 250+ bps expansion needed
ABD Maestro from ₹40 Cr (FY26) expected to ₹80 Cr (FY27)
UpgradeLuxury portfolio revenue doubling YoY. 10 brands, 5,500+ premium touchpoints, expanding into Odisha/Telangana. Still unprofitable and immaterial to consolidated results, but trajectory disclosed
Telangana overdue quantified at ₹400 Cr
NewMaterial disclosure: broadly old overdue cleared, but ₹400 Cr remains. Recent supplies on time. No explicit risk flagging beyond statement that government 'responsive to industry issues'
Supply chain ₹24 Cr impact; recovery timeline Q2 max
NewMD expects supply chain pressure 'maximum up to Q2,' with Q3–Q4 bounce-back. Vague timeline; dependent on geopolitical de-escalation (implied reference to Middle East conflict)
The Q&A
Analysts pressed hard on growth gap: Q1 1.8% vs mid-teens guidance. MD deflected to industry outperformance (11.6% P&A growth vs single-digit industry) and blamed temporary supply chain. On brand relaunches (Officer's Choice Blue, B7), management was defensive—acknowledged high-teens volume decline but offered future relaunch as remedy, not current recovery proof. Telangana price hike questioned; MD was optimistic ('80% of states granted increases in 3 years') but noncommittal on timing. Overall tone: confident but not transparent on downside scenarios.
ABD Maestro capacity & cost — Abneesh Roy, Nuvama
Partial10 brands launched FY26, now penetrating; ~5,500 premium outlets, expanding. Revenue ₹40 Cr FY26 to expected ₹80 Cr FY27. Costs not mounting further; 3-year gestation typical for luxury; too early to comment on profitability.
Guidance & Telangana risk — Abneesh Roy, Nuvama
DodgedWilling to upgrade guidance to high-teens revenue + 18% EBITDA (from mid-teens base). Dialog with Telangana ongoing; built in guardrails. 80% of states granted price increases in 3 years; very hopeful.
Telangana overdue — Dhiraj Mistry, Jefferies
Answered~₹400 crores. Mostly old overdue now paid; recent supplies on time. Government being billed, so payment risk low.
Weak non-ICONiQ P&A brands — Dhiraj Mistry, Jefferies
PartialPost-listing cash flow constraints now behind. Officer's Choice Blue getting new packaging/communication (already in UP market). B7 due for brand reset (new look coming H2 FY27). Two large brands in same price bracket as ICONiQ; relaunches will help premium portfolio.
White space launches — Dhiraj Mistry, Jefferies
AnsweredH2 FY27: vodka (15–18M case market, unchallenged leader, high contribution) and premium whisky (uniquely packaged, new concept). Both will see light of day in H2 FY27.
Q1 growth gap vs FY27 guidance — Kaustubh Pawaskar, ICICI Direct
PartialQ1 impacted by industry-wide supply chain headwinds. ABD outperformed: P&A up 11.6% vs industry mid-single digit, overall +6.2% vs industry low single-digit. Q3–Q4 recovery expected; new OC Blue relaunch, ICONiQ momentum, brandy in AP, deluxe vodka, premium whisky launches. With backward integration benefits, margins and volume will deliver mid-teens.
Telangana old overdue breakdown — Kaustubh Pawaskar, ICICI Direct
DodgedBroadly old overdues cleared; certain overdues still awaiting government clearance; new supplies paid on time.
Price increase opportunities — Kaustubh Pawaskar, ICICI Direct
PartialTelangana in sight after first 2 quarters margin pressure. 1–2 other states possible but too early to disclose.
Guidance disconnect — Ishan Modi, individual investor
DodgedNo disconnect. Mid-teens guidance was prior; MD reviewing upward based on new brand launches, packaging revamps, capex becoming margin-accretive. Official guidance to be formally updated if conditions hold.
FY27 margin guidance & ABD Maestro ARR — Ishan Modi, individual investor
AnsweredStick to FY26 margin level (~12.2%). ABD Maestro too early stage to disclose revenue; just seeded last year, penetration phase this year.
P&A relaunch downside risk — Ishan Modi, individual investor
PartialICONiQ grew 33.8% Q1, 87.8% FY26; targeting ~15M cases FY27 (from 10.7M FY26, ~10% growth). Alongside other brand launches, volume growth numbers protected.
ICONiQ headroom & competitive position — Sanjay, DAM Capital
AnsweredHeadroom in Karnataka, Telangana, Andhra Pradesh. Just listed in defense CSD channel. 3 meaningful brands in prestige category; other 2 facing challenges (will capitalize). Aiming ICONiQ 10.7M → ~15M cases FY27. Export markets also expanding (10 countries).
ENA backward integration plan — Sanjay, DAM Capital
PartialCurrent capex (Maharashtra, Telangana expansions) sufficient for captive utilization at 100%. Next 3 years transformational growth; may require external sourcing if growth exceeds plan. For next 4 years, planned ENA expansion will meet captive needs.
ABD Maestro brand-level performance — Sanjay, DAM Capital
DodgedWoodburns, Arthaus (blended malt), YELLO Whisky, Zoya Gin showing excitement. Zoya could be serious contender to luxury gin leader. All brands growing, cautious on aggressive push to avoid discounting. Too small to disclose individual numbers.
Guidance
FY27 mid-teens (potentially high-teens per MD) revenue growth
MediumQ1 delivered 1.8% growth. Recovery dependent on supply chain normalization (Q2 max), new brand launches (H2), and accelerating ICONiQ. Relaunch of existing brands (OC Blue, B7) critical but unproven
ICONiQ White 10.7M cases FY26 → ~15M cases FY27 (~40% growth)
HighBrand momentum strong; new distribution channels (CSD defense listing), geographic expansion (Karnataka, Telangana, AP), international growth. Management confident; history of execution (87.8% FY26)
FY27 EBITDA margin 'broadly in line with FY26' (~12.2%)
LowQ1 delivered 12.2%; any margin expansion absorption by supply chain costs, ABD Maestro investment, and new brand launches. No guidance of improvement FY27
FY28 EBITDA margin 17–18% (vs FY27 ~12.2%)
MediumUnderpinned by: backward integration 300 bps benefit by FY28, India-UK FTA 70–80 bps H2 FY27 (130–140 bps full FY28), operating leverage, cost discipline. Requires Telangana price hike (unconfirmed) + supply chain normalization + relaunch success
Capex funding: internal accruals + debt; maintain leverage within guidance
HighCurrent capex cycle (PET, malt, ENA, bottling) across Telangana, Maharashtra, UP, AP; backward integration expected to drive structural margin accretion over medium-term
Backward integration capex: 300 bps EBITDA benefit by FY28, +100 bps by FY29
MediumPET facility (Rangapur) commissioned FY26, now EBITDA accretive. Malt distillery expected H1 FY27; full capex plan (ENA, malt, PET, bottling) across multiple states. Margin levers concrete but dependent on execution & pricing
Risks the call surfaced
Government receivables
MediumTelangana government overdue ₹400 Cr; mostly old overdue in process, but new supply payment terms remain uncertain. Material impact on working capital if collection delayed
Supply chain disruption
Medium₹24 Cr supply chain impact in Q1 (2.6% of revenue). Management expects recovery by Q2, but geopolitical risk (Middle East conflict, Ukraine) could extend disruption into H2, undermining margin guidance
Brand portfolio concentration
MediumICONiQ White driving 33.8% of P&A growth; non-ICONiQ P&A brands (Officer's Choice Blue, B7, B10) in structural decline (~high-teens CAGR loss). Over-reliance on single brand; relaunch bets unproven. If ICONiQ growth stalls or relaunches fail, overall P&A growth collapses
Guidance execution risk
HighMid-to-high teens FY27 revenue guidance vs Q1 actual 1.8% growth requires 20%+ H2 acceleration. Guidance assumes supply chain recovery, successful brand relaunches, Telangana price hike, and continued ICONiQ momentum—multiple bets. If any fails, guidance will be cut, damaging credibility
Margin target credibility
MediumFY28 EBITDA margin target 17–18% requires 500+ bps expansion from Q1 12.2%. Dependent on backward integration benefit (300 bps, not yet materialized), India-UK FTA (130–140 bps, regulatory/timing risk), and Telangana price increase (uncertain). Any single lever failure jeopardizes target
Management
Score 6/10. MD is confident and articulate; uses industry-leading brand examples (ICONiQ, fastest-growing whisky) effectively. But evasive on specific numbers (ABD Maestro profitability) and downside scenarios. Q&A showed some defensive tone when challenged on growth gap; pivots to industry outperformance rather than explaining internal execution shortfalls Mixed track record. ICONiQ delivered 87.8% FY26 and 33.8% Q1 FY27—high execution bar. But non-ICONiQ brands (OC Blue, B7) in decline for 3+ years; relaunch promises unproven. PET facility delivered, malt still pending H1 FY27. Supply chain headwinds cited but partially self-inflicted (not hedged earlier). Overall: strong on premium brands, weak on portfolio turnarounds
1 · H2 FY27
Officer's Choice Blue relaunch (Q3), Sterling Reserve B7 relaunch (Q4)
2 · H2 FY27
Launch deluxe vodka and premium whisky to capture white spaces
3 · H1 FY27
Rangapur malt distillery becomes operational; backward integration eases malt constraints
Material Telangana receivables (₹400 Cr) add execution risk.
ABD Q1: consolidated PAT down 18.7% to ₹45 Cr on ₹24 Cr supply-chain hit; net sales +6%
PAT -18.65% YoY · revenue +1.85% · margins compressing
₹1,809.15 Cr
+1.85% YoY
₹45.42 Cr
-18.65% YoY
2.5%
-0.6pp YoY
₹1.76
Allied Blenders' consolidated net profit fell 18.7% YoY to ₹45.4 Cr even as net sales (excise-excluded) rose 5.8% to ₹984 Cr — the profit drop is a one-off story, not an operating one. Management attributes it to roughly ₹24 Cr of supply-chain disruption costs (glass and packaging); adjusting that pre-tax cost, underlying consolidated PAT was about +10% YoY. Reported gross revenue from operations was ₹1,809 Cr (+1.9%). Notably, standalone PAT actually rose 11.9% to ₹68.2 Cr — the >20-point divergence from the consolidated decline comes from widening subsidiary losses (nine subs, ₹3.7 Cr net loss) and a larger non-controlling-interest loss (₹3.8 Cr); consolidated owners' PAT was ₹49.2 Cr (−13%). Readers will see both figures, so neither is wrong.
Q1 FY-2027 vs prior quarters
The premiumisation thesis is visible in mix and gross margin — Prestige & Above is now 59.3% of value (from 55.8%) and gross margin expanded 277 bps to 46.0% — but it did not reach the bottom line. EBITDA was ₹120 Cr, roughly flat at ~12% of net sales, and below EBITDA the group carried a ~47% jump in depreciation (₹22.8 Cr) and ₹29.5 Cr of finance costs from its capex cycle, pulling PBT down 10.3% to ₹67.8 Cr and NPM to 2.5% from 3.1%. The quarter is clean at the exceptional line, unlike Q4 FY26 whose ₹26 Cr earlier-years tax charge depressed the base — so the headline +21% QoQ PAT is a base-and-seasonality artifact (Q1 is the summer peak) and should not be read as momentum.
The stock went into the print at ₹597.85, down 0.8% over the past month of trading.
Management guides for a strong recovery with double-digit top-line growth in Q4 FY26, driven by market normalization and continued momentum in the P&A portfolio. Long-term, the company targets an aggressive 17-18% EBITDA margin by FY28, underpinned by strategic backward integration capex, continued premiumization led b
— This quarter: missed
No pre-result consensus was on record and management gives no formal quarterly guidance; on the last concall (Jan 2026) it guided double-digit topline momentum and a ~300 bps EBITDA-margin build by FY28 led by ICONiQ White and the ABD Maestro portfolio. Net sales +5.8% falls short of the double-digit ambition, though the mix shift is on track. Concurrent corporate actions: the NCLT order for the Deccan Star/Sarthak merger, a ₹500 Cr Moradabad capacity expansion, and an SES ESG score of 58.70. The CSD arbitration (₹34 Cr claim) and the settled income-tax search matter remain in the notes with no P&L impact this quarter.
W1
Whether the ~₹24 Cr glass/packaging supply-chain disruption cost reverses next quarter — management flags it as the swing factor behind the ₹45 Cr PAT
W2
P&A mix and gross-margin trajectory toward the FY28 ~300 bps EBITDA-margin expansion target (EBITDA now ₹120 Cr, ~12% of net sales)
W3
Subsidiary/NCI drag (₹3.8 Cr NCI loss this quarter) and capex-led depreciation (₹22.8 Cr/qtr) as UTO Asia, KION and new capacity integrate